News | September 03, 2025
Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Triggering global regulatory submissions this year for the treatment of obesity
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Guidelines aim to establish state-regulated veterinary blood banks
Subscribe To Our Newsletter & Stay Updated
